At 6.5% CAGR, Biotechnology Separation Systems Market Size …

Apr 25, 2019 (Heraldkeeper via COMTEX) -- The Biotechnology Separation Systems market was valued at 16100 Million US$ in 2018 and is projected to reach 26600 Million US$ by 2025, at a CAGR of 6.5% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Biotechnology Separation Systems.

The Biotechnology Separation Systems market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Biotechnology Separation Systems market and the trends that will prevail in this industry.

Request a sample Report of Biotechnology Separation Systems Market at: https://www.marketstudyreport.com/request-a-sample/1548816?utm_source=Marketwatch.com&utm_medium=AN

The global market is further analyzed by the following types: DNA microarray, flow cytometry, liquid chromatography, membrane filtration, protein microarray, and others.

The classification of biotechnology separation systems includes membrane filtration, chromatography, centrifuge, electrophoresis, flow cytometry and others. The proportion of chromatography in 2015 is about 45.7%, and the proportion of membrane filtration in 2015 is about 17.3%. Others are also important in separation.

The application of biotechnology separation systems is commercial and scientific research. The most proportion of biotechnology separation systems is used in commercial, and the market share in 2015 is about 85.2%.

North America region is the largest supplier of biotechnology separation systems, with a revenue market share nearly 54.8% in 2015. Europe is the second largest supplier of biotechnology separation systems, enjoying Revenue market share about 28.2% in 2015.

What pointers are covered in the Biotechnology Separation Systems market research study?

The Biotechnology Separation Systems market report | Elucidated with regards to the regional landscape of the industry:

The Biotechnology Separation Systems market report | Elucidated with regards to the competitive landscape of the industry:

Ask for Discount on Biotechnology Separation Systems Market Report at: https://www.marketstudyreport.com/check-for-discount/1548816?utm_source=Marketwatch.com&utm_medium=AN

The Biotechnology Separation Systems market report | Elucidated with regards to some other pointers that would prove vital for stakeholders:

The Biotechnology Separation Systems market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Biotechnology Separation Systems market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

For More Details On this Report:https://www.marketstudyreport.com/reports/global-biotechnology-separation-systems-market-insights-forecast-to-2025

Some of the Major Highlights of TOC covers:

Biotechnology Separation Systems Regional Market Analysis

Biotechnology Separation Systems Segment Market Analysis (by Type)

Biotechnology Separation Systems Segment Market Analysis (by Application)

Biotechnology Separation Systems Major Manufacturers Analysis

Related Reports:

1. Global Mobile Phone Recycling Market Insights, Forecast to 2025 This report categorizes the Mobile Phone Recycling market data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors Analysis. Read More: https://www.marketstudyreport.com/reports/global-mobile-phone-recycling-market-insights-forecast-to-2025

2. Global Woofer Market Insights, Forecast to 2025 Woofer Market report starts from illustration of Industry Chain structure, and portrays industry condition, at that point investigations advertise size and figure of Woofer by item, district and application, likewise, this report presents showcase rivalry circumstance among the merchant's profile, plus, advertise value examination and esteem chain highlights are canvassed in this report. Read More: https://www.marketstudyreport.com/reports/global-woofer-market-insights-forecast-to-2025

Contact Us: Corporate Sales, Market Study Report LLC Phone: 1-302-273-0910 Toll Free: 1-866-764-2150 Email: sales@marketstudyreport.com

Read this article:
At 6.5% CAGR, Biotechnology Separation Systems Market Size ...

Global Biotechnology Reagents Market Growth Analysis, Forecasts to 2025 Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter Inc., Becton…

The global "Biotechnology Reagents Market" report offers precise analytical information about the Biotechnology Reagents market. The market experts and proficient analysts generate the information based on the past and current situation of Biotechnology Reagents market, various factors affecting the growth trajectory, global sales, demand, total revenue generated, and capitalization of the market. Moreover, the report delivers a summarized assessment of the impact of federal policies and regulations on market operations. It also comprises detailed information pertaining to the Biotechnology Reagents markets current dynamics. The global Biotechnology Reagents market acts as a huge platform that offers several opportunities for many reputed firms, organizations, manufacturers, vendors, and suppliers Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter Inc., Becton, Dickinson & Company, Biomerieux, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Biotime Inc, C.B.S. Scientific Company Inc, Cyano Biotech Gmbh, Ge Healthcare, Invivoscribe Technologies Inc, Lonza Group Ltd., Meridian Biosciences Inc. to compete with each other to become one of the globally and regionally leading business holders.

Click Here To Access The Sample Report:: https://www.promarketresearch.com/request-for-sample.html?repid=15442

For a thorough analysis, The report presents a demand for individual segment in each region. It demonstrates various segments Life Science Reagents, Analytical Reagents and sub-segments Protein Synthesis and Purification, Gene Expression, DNA and RNA Analysis, Drug Testing of the global Biotechnology Reagents market. The global Biotechnology Reagents market report delivers all-inclusive study about the business growth enhancers and obstructers, earlier and current trends being followed by the market, and the comparison between the global as well as regional revenue generation by the market. The brief study, about recent technological developments, detailed profiles of the leading firms in the market, and unique model analysis, is included in the report. The global Biotechnology Reagents market report offers a detailed review of micro and macro aspects that are essential for driving the business along with comprehensive value chain analysis.

Read Detailed Index Of Full Research Study @:: https://www.promarketresearch.com/global-biotechnology-reagents-market-2018-by-manufacturers-regions-15442.html

Apart from this, the market categorization based on the geography and region is included in the report. The global Biotechnology Reagents market research report delivers precise analysis for varying competitive dynamics. It offers a six-year forecast review revealing the anticipated futuristic growth of the market. The report delivers high-appreciated information to help the clients in taking appropriate steps for driving the business. The experts and analysts employ various statistical and mathematical approaches, along with advanced analytical methods, such as SWOT analysis, to generate valuable information, which is available in the global Biotechnology Reagents market report.

There are 15 Chapters to display the Global Biotechnology Reagents market

Chapter 1, Definition, Specifications and Classification of Biotechnology Reagents , Applications of Biotechnology Reagents , Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Biotechnology Reagents , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Biotechnology Reagents Segment Market Analysis (by Type);Chapter 7 and 8, The Biotechnology Reagents Segment Market Analysis (by Application) Major Manufacturers Analysis of Biotechnology Reagents ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Life Science Reagents, Analytical Reagents, Market Trend by Application Protein Synthesis and Purification, Gene Expression, DNA and RNA Analysis, Drug Testing;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Biotechnology Reagents ;Chapter 12, Biotechnology Reagents Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Biotechnology Reagents sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: https://www.promarketresearch.com/inquiry-for-buying.html?repid=15442

Reasons for Buying Biotechnology Reagents market

This report provides pin-point analysis for changing competitive dynamicsIt provides a forward looking perspective on different factors driving or restraining market growthIt provides a six-year forecast assessed on the basis of how the market is predicted to growIt helps in understanding the key product segments and their futureIt provides pin point analysis of changing competition dynamics and keeps you ahead of competitorsIt helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

See the original post here:
Global Biotechnology Reagents Market Growth Analysis, Forecasts to 2025 Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter Inc., Becton...

Genesis Biotechnology Group Acquires Assets of 4path, Ltd to Expand their Diagnostic Branch – Markets Insider

HAMILTON, N.J., Aug. 3, 2017 /PRNewswire/ --Genesis Biotechnology Group (GBG), a consortium of vertically-integrated entities that are concentrated in Drug Discovery and advanced, state-of-the-art molecular diagnostic services, such as next-generation sequencing and bioinformatics to aid in the detection of chronic complex diseases, announced today the asset acquisition of 4path, LTD (4path), an Anatomic and Clinical Pathology Laboratory facility located in Burr Ridge, IL. Financial terms were not disclosed.

Medical Diagnostic Laboratories, L.L.C. (MDL), a molecular diagnostic testing service company and a member of GBG, has a proven track record of service excellence and cost-efficiency through the effective use of advanced automation and robotic technology. With this collaboration, patients and providers in the Great Lakes region will have increased access to advanced molecular diagnostic assays and an expanded menu of cytopathology and histology services in multiple specialties such as Gynecology, Gastroenterology, Urology, Breast, Podiatry, and Dermatology. This collaboration also brings a dedicated sales force to expand 4path's relationship to clients in a larger geographic area, establish a rapid-response clinical laboratory to reduce turnaround time in the mid-west region, and fund future strategic growth initiatives.

According to Dr. Eli Mordechai, GBG's CEO, "This collaboration is an excellent fit with our mission to improve patient care and advance the quality of treatment options through the development and delivery of world class diagnostics. It brings together highly complementary services that enable clients to have access to a comprehensive portfolio of clinical diagnostic services in multiple therapeutic areas." This spirit of collaboration was supported by Stephen G. Ruby, MD, MBA of 4path, Ltd, who stated, "As Medical Director of 4path, I am pleased to have this relationship with the GBG family of healthcare businesses.We look forward to expanding the scope of services available to our physician base and providing them with the specialized laboratory support for their patients."

About GBGGBG is a consortium of vertically-integrated corporate diagnostic and research entities, which facilitates the overall market implementation and delivery of biomedical science products and services related to diagnostics and drug discovery. The Diagnostic segment of GBG utilizes high complexity, state-of-the-art, automated molecular analysis to offer clinicians from many different specialties valuable diagnostic information to assist in the detection, diagnosis, evaluation, and treatment of complex disease. Through the integration of research activities and the collaboration of diverse groups of scientists with expertise in molecular biology, genetics, high throughput screening (HTS), pharmacology, molecular modeling, and medicinal chemistry, GBG will be better positioned to provide complex diagnostic platforms in infectious disease, genetic-based testing, cancer diagnostics, and drug resistance profiling.

About 4path, Ltd4path, Ltd is a College of American Pathologists (CAP) Accredited Laboratory in the Chicago metropolitan area, which has provided Anatomic Pathology services to clients in the Great Lakes Region for over 10 years. Their team of board-certified pathologists provides highly personalized diagnostic services with expertise in Podiatry, Gastroenterology, Urology, Dermatology, Breast, Gynecology, Orthopedics and other specialties.

To find out more, please visit http://www.genesisbiotechgroup.com or http://www.4path.com.

Contact:

Ben Bandaru, Director of Mergers & Acquisitionsrel="nofollow">170782@email4pr.comDirect: 609.245.7507www.genesisbiotechgroup.com

View original content with multimedia:http://www.prnewswire.com/news-releases/genesis-biotechnology-group-acquires-assets-of-4path-ltd-to-expand-their-diagnostic-branch-300498985.html

SOURCE Genesis Biotechnology Group

Go here to see the original:
Genesis Biotechnology Group Acquires Assets of 4path, Ltd to Expand their Diagnostic Branch - Markets Insider

Degrees in Biotechnology | How to Have a Biotechnology Career

Biotechnology Careers At-a-Glance

The United States leads the pack in biotech revenue, market capitalization, and the number of public biotech companies, according to a 2015 report by Ernst & Young Global Limited. In 2007, three biotechnology companies made more than one billion dollars; by the end of 2014, that number had grown to 26, and there is no end in sight to the massive growth. Biotechnology careers can be found mainly in pharmaceutical companies including Gilead Sciences, Celgene, Biogen, and Regeneron, all companies named by Forbes among the top 10 biotech companies in the country.

People who choose biotech careers have several areas of specialization to choose from. A few options include working as an epidemiologist, microbiologist, biochemist, botany specialist, agricultural and food scientist or biomedical engineer. Graduates might wind up working in a laboratory, creating new seed lines, or in a vast field, testing new soil compositions. They might work to clone animals, develop new pharmaceutical drugs, create a bionic pancreas and so much more. No matter what the career path, it all begins with rigorous study and earning a biotechnology degree.

As with all statistics, salary numbers can be deceiving. There are two reasons why the numbers below should be taken into context.

First, biotechnology careers typically require a bachelors degree for entry, but the field is filled with people who also hold masters and doctoral degrees. For instance, 45 percent of the biomedical engineers who responded to an O*NET survey said a bachelors degree was sufficient; thirty-five percent needed a masters degree and a further 20 percent needed a doctorate. Those with advanced degrees typically have higher earning potential, which partially explains how some biomedical engineers can earn around $50,000 per year while others are clearing $140,000.

Second, there are multiple employers of the scientists listed below. Some of the most prominent are universities, which typically pay less than companies engaged in applied research. Companies make profits, which can be shared with employees; universities do not.

Working in the biotechnology field starts with the proper education. Though there are numerous pathways to the various professions, some steps to success are universal. Heres how to get there.

1

Begin with the right classes

Those interested in biotechnology careers can begin their journey by taking several biology or chemistry electives while in high school. Students should also look into pursuing courses that provide both high school and college credit, such as advanced placement.

2

Start with the bachelors degree

Once high school is over, its time to move into college and earn a bachelors degree in biology, biotechnology (if offered) or a closely related field. Though there are associate degrees in biology that will form a firm foundation for the bachelors, most entry-level positions in biotechnology will require at least a bachelors degree.

3

Get experience

Learning about the job and getting hands-on training in the field can look great on a resume, as well as provide students an opportunity to decide what area of biotechnology interests them the most. Some students choose internships during their college years, while others seek out part-time or full-time work with biotech companies or labs.

4

Pursue graduate studies

In many cases, biotechnology careers will require a graduate degree for advancement. Depending upon the chosen career path, students might need to embark on their masters degree or end up with a PhD in order to do the work they really want to do.

5

Stay up-to-date

Technology is always changing, growing and shifting. Some fields of biotechnology are moving so fast that they can literally change by the week. Thats why it is so important to stay up-to-date by subscribing to industry publications, becoming active in industry associations, keeping in touch with network contacts, and otherwise staying on top of what is happening in the field.

6

Seek out new opportunities in the field

Biotechnology careers offers quite a bit of overlap; for instance, a soil and plant scientist might choose to eventually work as an agricultural and food scientist, and their education might support both paths. Seeking out new opportunities to expand on a current profession is one of the perks of working in the field, and can lead to exciting possibilities.

Those who are interested in biotechnology will discover a dizzying array of possibilities for degrees; anything from the certificate to the PhD can be helpful during the career pursuit. In addition, many biotech degrees easily adapt to online study for students who dont have the ability to attend traditional classes. Heres an overview of which degrees might be more advantageous for certain situations.

I am excited to begin work in biotechnology. I need something that will allow me to get my foot in the door while giving me a strong foundation for graduate work.

I have been working in the field for years, but there are some points that I need to brush up on times have definitely changed these last few years, and Im ready to change with it. But leaving my job to go back to school is simply not an option, as finances would be too tight.

I already have my bachelors degree, but none of my classes focused on the high-level biology I need to know in order to move into the biotech field. I need to get a bit more education while I gain experience.

I definitely want to go into biotech but I have no idea where to begin. I want to test the waters a bit and leave my options open for changing my degree path when I find what I really want to do

I grew up on a farm and love working with animals. I want to be an animal scientist, so I can help make their lives better. Its a journey that will take some serious time and effort, but Im ready for the challenge.

Ive been working in the field for a while, but promotions and pay raises seem rather elusive one manager pointed out that my educational level is holding me back. Its time to remedy that problem.

Choosing the best biotechnology degrees can be tough, as there are so many options out there. However, the desired career path often provides clues to which degree might be best, as well as which level of educational attainment is expected. Heres what students can expect to learn from each.

There are two types of biotechnology certificate programs: Those that are designed for students who have completed their graduate studies and now need more specialized training, or those who have earned their bachelors degree but didnt get all the recommended courses to move into a biotech career. The latter scenario often applies to those who have earned their bachelors in another field but have now chosen a career change to the biotechnology field.

Most certificate programs take a year or less to complete, and are very focused on the particular educational path, with little to no general education courses. Some of the common courses in a certificate program include:

This course helps students understand structural organic chemistry, chemical thermodynamics, acid base chemistry, and reaction mechanisms.

Understanding of Lewis structures

Strategic use of reaction mechanisms

Knowledge of biological molecules and how they form and interact

Students will explore the ethical issues in biotechnology, including real-world case studies and current events in the field.

Applying philosophical theories to critical current issues

Conducting human experimentation in a compassionate and ethical manner

Ethical practices regarding animal testing

This class focuses on the regulatory approval process for drugs, foods, cosmetics and more.

Proper compliance with regulatory rules

Legal implications in regulatory issues

Ethical considerations when bring a new product to market

The associate degree in biotechnology prepares students to eventually move into the bachelors degree program. Though there are some employers who will accept students who have only the associate degree, many entry-level jobs do require the four-year education. The associate degree requires four years of study to complete, though some accelerated programs might allow completion in as little as 18 months. Some common courses found in the associate in biotech program include:

This course serves as an important overview for those who are interested in the biotech field, including a look at career options.

Use of safe laboratory procedures

Understanding the variety of potential careers and how they relate to each other

Applying the basics of biotech to day-to-day life

Students will learn quality assurance principles and how they relate to the biotech fields.

Understanding the differences in regulated and non-regulated work environments

Quality system usage, including Lean and Six Sigma

Theoretical views of quality assurance as applied to real-world events

Focuses on computational biology and bioinformatics as it relates to processes and end results.

Methods for high-volume data collection

Storing and accessing biological data

Use of common programs and algorithms to analyze data

For most careers in biotechnology including that of biomedical engineer, food scientist, microbiologist, plant and soil scientist, and agricultural engineer, among others a bachelors degree is required for entry-level work. The bachelors degree typically takes four years to complete and offers some opportunities for specialization through the use of electives under the biotechnology umbrella. Some classes that students can expect to take include:

Students explore the current research in biological science and analyze it according to biotechnology principles.

Critical analysis of current research

Use of scientific reasoning to make evaluative decisions

Understanding core biological concepts

Focus on the structure and function of cells, with an emphasis on eukaryotic cell biology.

Use molecular biology knowledge to draw research conclusions

Understand DNA replication and repair

The applications of genetic engineering

An in-depth look at safety procedures and proper management of laboratory spaces.

Management of personnel, space, inventory and equipment

Proper communications with stakeholders

Compliance with all safety and health regulations

The masters in biotechnology degree allows students to enhance their knowledge through a specialized curriculum. The masters in biotech is made up of a few core courses, which are then enhanced by electives that focus on the particular educational path a student wants to carve out for themselves. The masters degree takes two to three years to complete, depending upon the program. Many programs are available online, as schools recognize the need for a flexible schedule for those who are already working in the field.

Some courses that can be found at the masters level include:

Focuses on all the aspects of project management, such as working in teams, managing time, structuring projects and more.

Consideration of each phase of a project

Communicating with a wide variety of people involved in a project

Monitoring and controlling change

Students will learn the ins and outs of federal funding and regulations, writing grant proposals, and other sources of funding for research and development.

Students will study how to apply a comprehensive validation philosophy to new ventures in biotech.

Creating equipment or processes that are less prone to failure

Designing robust yet cost-effective projects

Creating validation documents in line with rules and regulations

The doctorate is the pinnacle of the biotechnology field, and offers students quite broad autonomy when choosing an original research project and focus of study. Those who intend to work with in-depth research or move into teaching will need to earn the PhD. Some professions require it, such as that of animal scientist or biophysicist. The doctoral program usually takes between three and four years to complete, though some schools allow up to eight years for completion of the dissertation. Some courses that might be found at the PhD level include:

Students will explore cutting-edge research areas and instruments, with a rotation that takes them through biomedical and biotechnology areas.

Familiarity with the latest technologies

Refresher on how to use instruments that considered out-of-date but might be advantageous for some projects

How to balance research between different laboratories and get the same results using different systems

Students will examine upper-level biotechnology or bio-engineering problems through the lens of equations and statistics.

High-level mathematics literacy

Advanced numerical methods

Refresher on statistical analysis

Students will engage in discussions with leaders in the field on current events and ethical issues that arise from the use of technology in the biological field.

Proper development of biological products

Conducting ethical biomedical research

Marketing and transparency in presenting new biotechnologies to the public

The U.S. biotech industry grew by just about every measure in 2014, according to Ernst and Youngs 2015 industry report. Revenue was up 29 percent, net income increased 293 percent and there were 164 more biotech companies than during the previous year. All of this meant one thing for jobs: There were a lot more of them. The industry added over 10,000 new jobs in 2014, which equates to a staggering 10 percent annual growth rate. Of course, not all of these jobs were for scientists and researchers many were for support staff one might find in any industry. Jobs specific to biotechnology involving research and development and manufacturing are outlined below.

The Bureau of Labor Statistics (BLS) combines three related careers under the heading of agricultural and food scientist: animal scientist, food scientist and technologist, and soil and plant scientist. Although all have the ultimate task of improving farm productivity, they accomplish this in different ways. Each are discussed separately here.

Many people dont think of farming as being sophisticated. Seeds are planted, crops are watered, and eventually food is harvested. But it is an extraordinarily advanced field, and the largest farms are essentially food factories. Engineers are involved in research and development as well as manufacturing. They might oversee water supply and usage, design comfortable areas for the animals, and create machines that can efficiently harvest crops with minimal food loss. Agricultural engineers spend their time both in offices designing systems and on farms testing and applying those systems.

See the rest here:
Degrees in Biotechnology | How to Have a Biotechnology Career

20th World Congress on Biotechnology and Biotech Industries Meet – Technology Networks

20th World Congress on Biotechnology and Biotech Industries Meet during March 05-07, 2018 at London, UK with a theme Future prospects for Biotechnology and Economic Growth. Conference Series LLC through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community.

Scope and Importance

Biotech Congress 2018 Conference aims to bring together the Professors, Researchers, scientists, business giants, and technocrats to provide an international forum for the dissemination of original research results, new ideas and practical development and discover advances in the field of biotechnology, management and education in relation to biotechnology as well as a breadth of other topics. The applications of biotechnology include therapeutics, diagnostics, genetically modified crops for agriculture, processed food, bioremediation, waste treatment, and energy production. Biotech Congress 2018 is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists.

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

Read the original here:
20th World Congress on Biotechnology and Biotech Industries Meet - Technology Networks

Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human … – Business Wire (press release)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has issued its Day-180 List of Outstanding Issues in the process of their ongoing regulatory review of Pumas Marketing Authorisation Application (MAA) for neratinib for the extended adjuvant treatment of HER2-positive early stage breast cancer in patients who have previously been treated with trastuzumab (Herceptin)-based adjuvant therapy.

The CHMP has requested additional data analyses related to the safety and efficacy of neratinib and has instituted a clock stop in order to allow Puma time to respond to this List of Outstanding Issues. The CHMP has set a deadline of December 22, 2017 for Puma to respond to the list. Puma expects the CHMP to issue an opinion regarding the MAA for neratinib in the first quarter of 2018.

U.S. Approval of Neratinib (NERLYNX)

Neratinib was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets.

About HER2-Positive Breast Cancer

Approximately 20% to 25% of breast cancer tumors over-express the HER2 protein. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery, up to 25% of patients treated with trastuzumab experience recurrence.

Indication

NERLYNX is a tyrosine kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

The full prescribing information for NERLYNX is available at http://www.NERLYNX.com. The recommended dose of NERLYNX is 240 mg (six 40 mg tablets) given orally once daily with food, continuously for one year. Antidiarrheal prophylaxis should be initiated with the first dose of NERLYNX and continued during the first 2 months (56 days) of treatment and as needed thereafter.

Important Safety Information

There are possible side effects of NERLYNX. Patients must contact their doctor right away if they experience any of these symptoms. NERLYNX treatment may be stopped or the dose may be lowered if the patient experiences any of these side effects.

Diarrhea

Diarrhea is a common side effect of NERLYNX. The diarrhea may be severe, and you may get dehydrated. Your healthcare provider should prescribe the medicine loperamide for you during your first 2 cycles (56 days) of NERLYNX and then as needed. To help prevent or reduce diarrhea:

Contact your healthcare provider right away if you have severe diarrhea or if you have diarrhea along with weakness, dizziness or fever.

Liver Problems

Changes in liver function tests are common with NERLYNX. The patients doctor will do tests before starting treatment, monthly during the first 3 months, and then every 3 months as needed during treatment with NERLYNX. NERLYNX treatment may be stopped or the dose may be lowered if your liver tests show severe problems. Symptoms of liver problems may include tiredness, nausea, vomiting, pain in the right upper stomach area (abdomen), fever, rash, itching or yellowing of your skin or whites of your eyes.

Pregnancy

Patients should tell their doctor if they are planning to become pregnant, are pregnant, plan to breastfeed, or are breastfeeding. NERLYNX can harm your unborn baby. Birth control should be used while a patient is receiving NERLYNX and for at least 1 month after the last dose. If patients are exposed to NERLYNX during pregnancy, they must contact their healthcare provider right away.

Common side effects in patients treated with NERLYNX

In clinical studies, the most common side effects seen in patients taking NERLYNX were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis (dry or inflamed mouth, or mouth sores), decreased appetite, muscle spasms, dyspepsia, changes in liver blood test results, nail problems, dry skin, abdominal distention, weight loss and urinary tract infection.

Patients should tell their doctor right away if they are experiencing any side effects. Report side effects to the FDA at 1-800-FDA-1088 or http://www.FDA.gov/medwatch. Patients and caregivers may also report side effects to Puma Biotechnology at 1-844-NERLYNX (1-844-637-5969).

Please see Full Prescribing Information, available at http://www.NERLYNX.com.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidatesPB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is approved for commercial use by prescription in the United States as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and is marketed as NERLYNX. NERLYNX is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of NERLYNX, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. The Company believes that NERLYNX has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types that over-express or have a mutation in HER2. Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the expected timing with respect to CHMP's opinion regarding the MAA for neratinib. All forward-looking statements included in this press release involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company currently has no product revenue, the Company's dependence upon the commercial success of NERLYNX (neratinib), the Companys history of operating losses and its expectation that it will continue to incur losses for the foreseeable future, risks and uncertainties related to the Companys ability to achieve or sustain profitability, the Companys ability to predict its future prospects and forecast its financial performance and growth, failure to obtain sufficient capital to fund the Companys operations, the effectiveness of sales and marketing efforts, the Companys ability to obtain FDA approval or other regulatory approvals for other product candidates, the challenges associated with conducting and enrolling clinical trials, the risk that the results of clinical trials may not support the Company's drug candidate claims, even if approved, the risk that physicians and patients may not accept or use the Company's products, the Company's reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates, risks pertaining to securities class action, derivative and defamation lawsuits, the Company's dependence on licensed intellectual property, and the other risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Company's Annual Report on Form 10-K for the year ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Link:
Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human ... - Business Wire (press release)

NJSBA magazine explores biotechnology and genetics – Yahoo News

The August issue of the New Jersey State Bar Association's bi-monthly magazine, New Jersey Lawyer, focuses on the evolving topic of biotechnology, genetics and the law.

"Although a very specialized area, biotechnology law crosses many legal disciplines, including litigation, licensing, intellectual property, patents, agriculture, business, venture capitalism, antitrust, biosecurity and bioethics," said Angela Foster and David Opderbeck, who served as special editors for the issue.

"The use of biotechnology has raised a number of legal, ethical and social issues, including who owns genetically modified organisms (GMOs), whether genetically modified foods are safe to eat, and who controls a person's genetic information. This issue explores contemporary biotechnology issues impacting the legal community."

A dozen articles explore the topic in the award-winning magazine, beginning with a look at whether organs-on-chips are patentable in an article by Douglas Bucklin. Richard Catalina Jr.'s article on the Biologics Price Competition and Innovation Act follows.

Nancy Del Pizzo's article looks at the open source model in biotechnology, while Foster explores the truth and fiction behind genetically modified food. Jonathan Lourie reviews strategic licenses and collaborations.

Reproduction is the topic of two articles, one analyzing assisted reproductive technology, written by Alan Milstein, and one penned by Kimberly Mutcherson on regulating the right to procreate.

Opderbeck's contribution focuses on synthetic biology and biosecurity, while Anjana Patel and Patricia Wagner discuss biotech mergers, acquisitions and antitrust issues and Marina Sigareva and Ryan O'Donnell look at global strategies for protecting biotech inventions.

The edition closes with articles on the Patent Trial and Appeal Board's influence on the biotech and pharma industries, written by Nichole Valeyko and Maegan Fuller, and the privacy implications for biotechnology by Wagner.

The October edition of New Jersey Lawyer will explore pro bono issues.

See more here:
NJSBA magazine explores biotechnology and genetics - Yahoo News

Nerium Biotechnology Shareholders Overwhelmingly Elect All Six Management Nominees to Nerium’s Board – Marketwired (press release)

SAN ANTONIO, TEXAS--(Marketwired - June 30, 2017) - Nerium Biotechnology, Inc. ("Nerium" or the "Company") is pleased to announce the voting results of its annual meeting of shareholders (the "Meeting") held on June 29, 2017 in Toronto, Ontario, Canada. This year's Meeting had extraordinary participation from Nerium's shareholders, with a total of 31,272,131 common shares, or approximately 85.75% of the outstanding common shares of Nerium, having been voted at the Meeting.

We are pleased to announce that Nerium's shareholders voted to elect all six of Nerium's director nominees to the board of directors (the "Board"). Each Nerium director nominee received at least 77% of the votes cast by shareholders present in person or represented by proxy at the Meeting. The dissident's director nominees each received 20% of the votes cast by shareholders, which includes the 7.48% of the votes cast by the dissident shareholders. The voting results of the election of directors are as follows:

"We thank Nerium's shareholders for their consideration and support during this process," said Richard Boxer, Chair of the Special Committee of Nerium's Board. "We are pleased that the Company's shareholders voted overwhelmingly to reject the dissident's nominees and elect all of Nerium's nominees to the Board. Your directors will continue to act in the best interests of Nerium and all of its shareholders, and are committed to addressing legitimate shareholder concerns. We intend to provide shareholders with a more detailed update on the Company's business in the coming weeks."

All other matters set out in the Company's management information circular were approved by the requisite majority of the shareholders at the Meeting.

About Nerium Biotechnology, Inc.

Nerium Biotechnology, Inc. is a biotechnology company involved in the research, product development, manufacture and marketing of Nerium oleander-based products. The Company's shares are not listed on any stock exchange or quotation system.

Forward Looking Statements: Statements made in this press release that relate to future plans, expectations, events or performances are forward looking statements. Forward-looking statements are not based on historic facts, but rather on current expectations regarding future events. They are based on information available to management and/or assumptions management believes are reasonable. Many factors could cause future events and outcomes to differ materially from those discussed in the forward-looking statements. Although the forward-looking statements are based on what management believes are reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with these forward-looking statements. The forward-looking statements in this press release are made as of the date hereof and, except as required by applicable securities laws, the Company does not assume any obligation to update or revise such forward-looking statements. More information about the Company is available in its disclosure documents, all of which are available on the Company's issuer profile on SEDAR at http://www.sedar.com.

Link:
Nerium Biotechnology Shareholders Overwhelmingly Elect All Six Management Nominees to Nerium's Board - Marketwired (press release)

Biotechnology Separation Systems Market 2017 Industry Analysis, Size and Share – World Of WallStreet

Biotechnology Separation Systems Market

Overview

The report on the Global Biotechnology Separation Systems Market 2017 gives complete view of the market across the globe. In-depth analysis comprising key market players, market forecasts, supply, demand, profit, latest market trends, and many more are provided in the report below. The future aspects impacting the global market in every possible way are also further discussed in the report.

What our report offers:

View Free Sample Report @ http://www.marketresearchstore.com/report/global-biotechnology-separation-systems-market-by-manufacturers-regions-95565#RequestSample

Biotechnology Separation Systems Market: Research methodology

To Know More, Ask Our Expert @ http://www.marketresearchstore.com/report/global-biotechnology-separation-systems-market-by-manufacturers-regions-95565#InquiryForBuying

Additional information provided in the report

In addition, considering that the global economy is ever-changing depending upon several factors , it is important to take a note that our report contains data that are not only conducted regarding CAGR forecasts but it also analyzes the key parameters such as yearly market growth in order to have complete information about the future of the market worldwide. It also helps in identifying the wide opportunities that will open up for the market. The other key feature included in this report is the analysis of the revenue forecasts of all the important regions and applications, which is in terms of dollars.

About Market research Store

Market Research Store is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. Market Research Store is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading publishers and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.

Contact Us:

Joel John 3422 SW 15 Street, Suit #8138, Deerfield Beach, Florida 33442, USA USA Tel: +1-386-310-3803 GMT Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: sales@marketresearchstore.com Web: http://www.marketresearchstore.com/

More here:
Biotechnology Separation Systems Market 2017 Industry Analysis, Size and Share - World Of WallStreet

Director General of Nigeria’s biotechnology agency arrested over N23 million fraud – Premium Times

The Economic and Financial Crimes Commission, EFCC, says it has arrested Lucy Ogbadu, the Director-General of National Biotechnology Development Agency (NABDA), over alleged N23 million fraud.

The spokesperson of the commission, Wilson Uwujaren, disclosed this in a statement he issued on Thursday.

Mr. Uwujaren said Ms. Ogbadu was picked up by EFCC operatives in Port Harcourt on Wednesday, following her alleged link with the Bayelsa State Director of Bio-resources Development Centre, Josiah Habu.

Mr. Habu, according to him, is being investigated by the anti-graft agency in a case of fraudulent diversion of N75 million.

He said investigations by the EFCC revealed that Ms. Ogbadu allegedly received N23 million through a bank account belonging to the wife of Mr. Habu, Esther Habu.

The EFCC spokesperson stated that Ms. Ogbadu admitted the transaction in a voluntary statement made to the commissions investigators.

Further investigations also revealed that Mrs Habu is one of the contractors with Bio-resources Development Centre, Odi, Bayelsa State.

A total of N603 million has been traced to her in different deals involving over 20 directors of the centre across the country.

Ogbadus involvement is being investigated. She has been duly served with bail conditions while investigations continue, Mr. Uwujaren added.

Ms. Ogbadu, a professor of microbiology, was appointed NABDA director-general in November 2013.

(NAN)

See the original post:
Director General of Nigeria's biotechnology agency arrested over N23 million fraud - Premium Times

Explore Innovations in Industrial Biotechnology at Upcoming … – Newswise (press release)

Newswise Industrial biotechnology scientists, educators, entrepreneurs and executives from around the globe will be convening on the University of California San Diego campus this summer to explore the latest advances and world-changing innovations heating up the white-hot field of industrial biotechnology with workshops in microbial fermentation and metabolic engineering.

UC San Diego Extension will host its annual Industrial Biotechnology Workshops on Aug. 14 through 18. Participants can attend the whole program or attend the workshops on microbial fermentation or metabolic engineering separately.

Now in its fifth year, this widely acclaimed educational event creates an informal, intimate environment for robust exchange of knowledge and ideas among world-class academic instructors and leaders of cutting-edge companies of every size from startup to mature, said Hugo Villar, associate dean of Professional & Continuing Education for UC San Diego Extension.

Whether from California or China, biotechnology professionals attending these workshops will have a front-row seat to learn about current developments and advanced scientific skills being used to solve some the worlds most difficult problems, Villar said.

Microbial Fermentation

For the past four years, the workshop focused primarily on microbial fermentation, which is the transformation of feedstocks, such as plant sugars, into useful products, like fuels, chemicals, beer or antibiotics, by bacteria, yeast, fungi or algae.

The Microbial Fermentation Workshop will be held Aug. 16 to 18. Participants will be introduced to the fundamental knowledge and practical skills needed to design, develop, optimize, control, scale-up, analyze and troubleshoot fermentation processes.

As one of just a handful of programs in the world that provide in-depth, practically oriented coursework in microbial fermentation, it is expected to draw participants from Connecticut to Croatia.

While workshop participants should have some basic knowledge and experience in fermentation, everyone from scientists to biotech business executives to graduate students could benefit from the microbial fermentation workshop.

This years program features some of the brightest minds in the field, including:

Jeff Lievense, senior advisor of Bioengineering & Technology, Genomatica;

Rachel Dutton, assistant professor of Molecular Biology, UC San Diego;

Michael Japs, senior director of Process Technology, Genomatica;

Jon Hansen, principal of New Leaf Biotech;

Jason Ryder, vice president, Process R&D, Hampton Creek; and

Karen Fortmann, senior research scientist, White Labs.

Five interactive case studies, including production of microbes for cheese and beer, will allow attendees to practice what they learn, while the Fermentation Firing Line segment will offer a lively, open ended forum for posing questions to the instructional team on fermentation-related topics.

In addition, everyone in attendance can participate in a tour of the global headquarters of White Labs, which produces yeast for beer making, and attend a hosted reception in its craft beer tasting room.

Metabolic Engineering

A new segment on metabolic engineering, which will run Aug. 14-15, will also be offered.

Recently named as one of the top 10 emerging technologies by the World Economic Forum, metabolic engineering focuses on the design and development of equipment and processes for manufacturing products such as agriculture, food, animal feed and pharmaceuticals.

Instructors joining the interactive course with case studies throughout the curriculum include:

John Pierce, MIT lecturer and former scientist at multinational firms BP and DuPont;

Adam Feist, project scientist, UC San Diego;

Ben Griffin, senior director, Microbial and Enzyme Engineering, Synthetic Genomics;

Jeff Lievense, senior advisor, Genomatica;

Jim Mills, chief technology officer, BioAmber, Inc.;

Bernhard Palsson, principal investigator, UC San Diego; and

Kristy Salmon, head of research, BP.

Those who attend the Metabolic Engineering segment are also invited to participate in a tour of the global headquarters of White Labs, which produces yeast for beer making, and attend a hosted reception in its craft beer tasting room.

Those interested in finding out more about the upcoming workshops can visit http://extension.ucsd.edu/industrialbiotech , call (858) 534-9353 or email unexbio@ucsd.edu.

See the original post:
Explore Innovations in Industrial Biotechnology at Upcoming ... - Newswise (press release)

AML: Cellectis testing allogenic CAR-T cell therapy – European Biotechnology

Genome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia.

The company said it enrolled the first patient with acute myeloid leukaemia (AML) to be treated with UCART123 at Weill at Cornell Medicine, New York Presbyterian Hospital. UCART123 is a TALEN-genome edited chimeric T cell receptor targeting the CD123/IL3R antigen on the surface of blasts and dendric cells, which is administered on allogeneic donor T cells. The team of Gail J. Roboz will investigate the safety and will collect first indications for efficacy of UCART123 in patients with AML. The Phase I trial is part of a strategic translational research alliance that was formed between Cellectis and Weill Cornell Medicine in 2015.

While Novartis AG and Kite Pharma are leading the CAR-T cell therapy development in AML, Cellectis hopes to overtake its competitors. It has the only approach that works with allogenic CAR-engineered T cells that could be centrally pre-manufactured in contrast to the autologous patient T cells. Those need to be isolated, engineered and expanded during the at least 14 day hospital stay of the patients to be treated making the procedure costly, lengthy and laborious. On the other hand, Cellectis therapy does not target the CD19 T cell antigen but CD123//IL3R giving the company another unique selling point.

Cellectis has used TALEN technology to block expression of the TCRa constant (TRAC) gene though blocking expression of the natural TCR. According to Andr Choulika, Cellectis CEO, TALEN technology shows less off-target effects compared to CRISPR/Cas9 genome editing. Following apheresis, donor T cells are engineered to express an anti-CD123 CAR (CD123 scFv-41BB-CD3z) and an RQR8 depletion ligand that confers susceptibility to rituximab. Theoretically, specifity of of UCART123 therapy might be higher in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) than in patients with AML as CD123 expression is 10fold higher in the precursors of plasmacytoid dendritic cells than in blast occurring in the course of AML.

Cellectis also announced two new entries to ists Board of Directors. Ex-Novartis pharma division head Rainer Boehm will lead commercialisation of Cellectis lead candidate. Ex Novartis Oncology President and Incyte Corp CEO Herv Hoppenot will lead clinical development.

See the original post:
AML: Cellectis testing allogenic CAR-T cell therapy - European Biotechnology

Puma Biotechnology (PBYI) Earns Slightly Unfavorable Press Analysis, Based On In-Depth Analysis – Insider Tradings

Press articles about Puma Biotechnology (NYSE:PBYI) has been popular fairly negative last few days, Accern reports. The analytics team pointing out the bullish and bearish news analysis by observing larger than 20 Million public financial documents, market websites and SEC sources in real-time. Accern grades analysis of public companies ranging from -1 to 1, with ranks nearest to 1 is considered more positive. Puma Biotechnology achieved a news impact rank of -0.01 on Accerns range. Accern issued stories about the biopharmaceutical company a media impact point of 66 out of 100, pointing that recent news analysis is likely to impact the share value upcoming future.

Puma Biotechnology (NYSE:PBYI) previously disclosed its earnings report on early Wed, May 10th. The biopharmaceutical business posted ($1.97) Earnings per share for the period, reaching the Thomson Reuters average forecast of ($2.06) by $0.09. Brokerage firms predict that Puma Biotechnology to post ($8.50) earnings per share for the full year.

Puma Biotechnology (NYSE:PBYI) transacted up 4.71% throughout intraday market trading on early Wed, topping $88.85. the share had a trading volume of 872,030 Stocks. Puma Biotechnology has a 52 week low of $27.64 and a 52 week high of $92.00. The stocks market valuation is $3.28 B. Companys 50 Day SMA is $59.74 and its 200 day SMA is $42.39.

PBYI has been the topic of many Study analysis. Citigroup boosted Puma Biotechnology to a buy recommendation and fixed a $105.00 target price for The corporation in a study note on Sunday, May 28th. Zacks Lowered Puma Biotechnology from a buy recommendation to a hold recommendation in a analysis note on early Wed, Jun 14th. Stifel Nicolaus reiterated a buy recommendation and fixed a $105.00 target price on stock of Puma Biotechnology in a study note on early Mon, Jun 5th. J P Morgan Chase & Co reissued an overweight recommendation and fixed a $89.00 target price on stock of Puma Biotechnology in a study note on early Tue, Jun 6th. Lastly, Royal Bank Of Canada boosted their target price on Puma Biotechnology from $60.00 to $88.00 and issued the shares a sector perform recommendation in a analysis note on Tue, Jun 6th. 1 investment expert has recommended the share with a sell recommendation, two have published a hold recommendation and six have published a buy recommendation to The corporation. Puma Biotechnology currently has a average recommendation of Buy and an consensus price target of $86.94.

In other Puma Biotechnology news, large stockholder Adage Capital Partners Gp, L.L unloaded 507,128 stocks of the firms shares in a trade on early Mon, Jun 5th. The stock was unloaded at a price range of of $87.84, amounting $44,546,123.52. The information was declared in a transaction filed with the securities and exchange commission, which is available through the Security and Exchange Commission website. executive have unloaded 1,990,088 stocks of company shares valued $157,553,113 during the last ninety days. Executives own 22.70% of the firms stock.

Here is the original post:
Puma Biotechnology (PBYI) Earns Slightly Unfavorable Press Analysis, Based On In-Depth Analysis - Insider Tradings

Red Biotechnology Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 – Instant Tech News

New Jersey, United States The report is a comprehensive research study of the global Red Biotechnology market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Red Biotechnology global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

Red Biotechnology Market was valued at USD 314.2 Billion in 2018 and is projected to reach USD 503 Billion by 2026, growing at a CAGR of 5.7% from 2019 to 2026.

This report covers a comprehensive study of the data affecting the Red Biotechnology market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Red Biotechnology market.

Key players in global Red Biotechnology market include:

Amgen F. Hoffmann-La Roche, Gilead Sciences CSL, Pfizer Inc

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=11405&utm_source=ITN&utm_medium=005

Global Red Biotechnology Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Red Biotechnology s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Red Biotechnology Market :

Red Biotechnology market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Red Biotechnology Market : Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Red Biotechnology Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Red Biotechnology Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Red Biotechnology Market , By Deployment Model

5.1 Overview

6 Red Biotechnology Market , By Solution

6.1 Overview

7 Red Biotechnology Market , By Vertical

7.1 Overview

8 Red Biotechnology Market , By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Red Biotechnology Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/red-biotechnology-market/?utm_source=ITN&utm_medium=005

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]iedmarketresearch.com

Red Biotechnology Market Size, Red Biotechnology Market Analysis, Red Biotechnology Market Growth, Verified Market Research

See the original post here:
Red Biotechnology Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 - Instant Tech News

With $15M Series A, Culture Biosciences Is Growing Cells In The Cloud – Forbes

These internet-connected bioreactors can be programmed to grow engineered cells under optimal ... [+] conditions, allowing researchers around the world to churn out animal-free leather, biologic drugs and other advanced bioproducts.

As someone immersed in the biotechnology sector, Ive seen my share of startup stumbles. Giddy teams of brilliant scientists promising the next generation of this or sustainable that often fail to deliver, not because their core ideas are faulty but because they so often fail to get their arms around the true complexity of manufacturing.

Having a great idea for how biotechnology might improve lives is one thing think compostable plastics or alternative meats. But bringing those bold visions into reality is quite another.

Thats where Culture Biosciences comes in. Based in South San Francisco, the company has been stocking up on the type of expensive laboratory equipment bioreactors that most other biotechnology firms pour millions of dollars into. Culture then rents its physical lab equipment out to paying customers via an online portal. Think AWS, but for biology.

In this way, Culture is aiming to permanently reduce the complexity of biomanufacturing, allowing its customers to skip expensive investments in equipment and bring their goods to market sooner.

Culture today announced that it plans to triple its bioreactor capacity thanks to a new $15 million Series A, led by Cultivian Sandbox Ventures with participation from The Production Board and existing investors. For full disclosure, Im also an investor in this company through my role as an Operating Partner at DCVC.

Bioreactors are used to grow cells, which in turn can grow almost anything. Recent breakthroughs in synthetic biology now mean that scientists can program living cells more precisely than ever. Synthetic biology and biofabrication hold the answers to so many of the challenges we face today, says Will Patrick, Cultures co-founder and CEO.

We spent time talking to scientists working in industrial biotechnology, learning about their work in detail. There were so many companies working on potentially game-changing products, ranging from alternative food proteins to bio-based chemicals to life-saving medicines. Yet, they all faced formidable challenges in taking their lab-scale discoveries and turning them into commercially viable products at scale. We heard time and time again that the process of scaling-up from the bench to production was time-consuming, risky, and expensive. There were also so many stories about potentially promising products failing to be scaled-up to production successfully.

Culture already services some notable customers, including Zymergen, which is breeding microbes that produce value-added molecules for a number of industries, and Clara Foods, which is working to fast-track new sources of animal-free protein. Other new customers include Nektar Therapeutics, C16 Biosciences, and Boost Biomes.

Its a business model built on trust. As Culture expands, its stockpile of bioreactors which could soon exceed 300 must keep up with customers demands. By offering a reliable cloud service that can quickly be scaled up or down according to need, Culture hopes to save its customers lots of money in the long run.

Our mission is to build an end-to-end platform where bioprocess scientists can manage their entire workflow in our software application, said Patrick. In our conversations with scientists, we identified the bench-scale bioreactor lab as a key bottleneck in the scale-up process. Running bench-scale bioreactors to screen strains and develop bioprocesses is critical for developing new products, but it is also time-consuming, labor-intensive, and expensive.

At the moment, Patrick tells me that his customer base is roughly 60 percent biopharma and 40 percent industrial biotechnology. But I think it will flip. Im really big on the industrial biology sector. These spaces are massive, and the opportunity is so huge.

Platforms that broadly enable scientists, engineers, and innovators to do more for less could add fuel to the already hot synthetic biology sector. I recently wrote about how innovations in bio-nylon could soon unlock a $10 billion sector, how investments into synthetic biology made here on Earth could aid in 21st-century efforts to explore and inhabit space, and how synthetic biology companies are now racing to stop coronavirus.

Disruptors like Culture Biosciences renew my hope that this biological revolution is here to stay.

Follow me on twitter at@johncumbersand@synbiobeta. Subscribe to my weekly newsletters insynthetic biologyandspace settlement.

Thank you toIan Haydonfor additional research and reporting in this article. Im the founder ofSynBioBeta, and some of the companies that I write aboutincludingCulture Biosciencesare sponsors of theSynBioBeta conferenceandweekly digestheres the full list of SynBioBeta sponsors. I'm an operating partner at DCVC, which is an investor in Culture Bioscience.

Read the rest here:
With $15M Series A, Culture Biosciences Is Growing Cells In The Cloud - Forbes

Industry Analysis: Should You Buy Heron Therapeutics Inc (HRTX) in Biotechnology? – InvestorsObserver

Heron Therapeutics Inc (HRTX) is near the top in its industry group according to InvestorsObserver. HRTX gets an overall rating of 56. That means it scores higher than 56 percent of stocks. Heron Therapeutics Inc gets a 66 rank in the Biotechnology industry. Biotechnology is number 54 out of 148 industries.

Click Here to get the full Stock Score Report on Heron Therapeutics Inc (HRTX) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Heron Therapeutics Inc (HRTX) stock is trading at $24.35 as of 9:56 AM on Thursday, Jan 23, a loss of -$0.18, or -0.73% from the previous closing price of $24.53. The stock has traded between $24.02 and $24.55 so far today. Volume today is light. So far 82,435 shares have traded compared to average volume of 1,250,411 shares.

To see the top 5 stocks in Biotechnology click here.

View post:
Industry Analysis: Should You Buy Heron Therapeutics Inc (HRTX) in Biotechnology? - InvestorsObserver

A case of wholehearted biotechnology adoption – The Hindu

In the Editorial page article, The flawed spin to Indias cotton story (January 23, 2020), there are unfounded claims about a technology that has in reality been a boon to farmers across the world.

The first point made in the article is that GM cotton covers 95% of the area under cotton and that there are no choices for farmers. The fact: Indian farmers have voted for choice of seeds with biotechnologies by planting hybrid cotton biotech seeds on over 90% of the countrys cotton acreage. They want seeds and technologies that provide optimal yield, income and convenience in cultivation. Today, they choose from over 800 hybrid Bt cotton seed brands from over 40 Indian and global seed companies, with five approved in-the-seed insect protection Bt cotton technologies and non-Bt varietal cotton seeds. Farmers have not shown any preference for planting non-Bt cotton seeds including the quantity supplied along with the Bt cotton seed by seed companies as per regulatory guidelines.

Several key studies by third-party economists and sociologists have established that 85% of hybrid Bt cotton seed farmers and farm labourers invested in better education for children; 77% reported better intake of nutritious food; 75% reported better health of their family members; 64% invested on the health of livestock; female workers on Bt cotton fields earned an average 55% higher income; and 42.4 crore additional days of rural employment have been generated, thereby doubling cotton production.

Indias farmers are the ones who have reposed trust in biotechnology, making India the worlds second largest cotton producer and exporter by doubling cotton production over the past decade.

Cotton Corporation of India data show that the highest production of 398 lakh bales of cotton in India was achieved in 2013-14, valued at around 72,000 crore. Additional incomes were generated from cotton seeds oil (1.3 million tons) and cotton seed oilmeal (11 million tons) worth 13,000 crore and 22,000 crore, respectively. The Bt cotton seed market is about 3,000 crore, making it hardly 2.5% of the total value generated.

The articles second point is about low productivity as compared to the global scene. The fact is that technology has not only increased yields but also greatly reduced pesticide use. Biotechnology in cotton, post its introduction in 2002, has led to transformational changes in Indias cotton cultivation. These have helped increase cotton yields by over 1.8 times from 241 kg/hectare in 2002-2003 to 541 kg/hectare in 2018-2019. A BKS-CSD study shows that the significant increase in farmer incomes from higher yields and reduced pesticide use has generated additional farm income of over 42,300 crore. India is moving to first place as the largest producer of cotton in the world.

However, it is not just the technology that increases yields. Indias farmers face numerous uncertainties and crop management challenges, affecting farm yield and incomes; knowledge of cultivation and correct agronomic practices can make a significant impact. This is being addressed by numerous extension efforts.

There is an opportunity to increase yields further in India when compared to other countries that have been using even more advanced GM traits than what is being used in India. New technology introduction has stopped in India since 2005, affecting growth of yields.

The articles third point is about the availability of low cost manual labour. The fact is that one of the major challenges lies in securing labour to conduct field operations. Today, labour accounts for over 58% of a farmers cost of cultivation per acre. In a fast-evolving global market, Indias farmers instead need the best technologies to remain competitive.

The next claim is about varieties offering farmers increased benefits than hybrid cotton seeds. The fact is that Indian farmers who were using varieties for years switched to hybrids in the mid-1980s mainly because of the enormous benefits. Cotton Advisory Board data show that Indias cotton yields which were at 169 kg/hectare in 1980-81 increased to 278 kg/hectare in 2000-01 and then 542 kg/ hectare in 2016-17.

The writers argument that High Density Planting (HDP) took place in various countries after introduction of biotech cotton is inaccurate. Planting rates are determined by several agronomic and environmental conditions and not based on biotech versus non-biotech. There is also no change in the seed rate in any of the countries in which biotech cotton has been adopted. HDP has done well in India because of the better quality of germplasm.

Also, Turkey is not a large cotton producer. USDA statistics in 2017-18 shows that India leads with 35m bales, followed by China (28m bales), the U.S. (21m bales), Brazil (9m bales) and Australia (5m bales). All of them are GM cotton countries, contributing to more than 90% of global cotton production. GM cotton was introduced in Brazil in 2006-07.

India also produces hybrid cotton seed because of the availability of labour to carry out the hand pollination at reasonable cost; this is not available in the U.S., Brazil, Australia and China. Hybrid cotton has delivered not only higher yields but also provided resistance to some pests and diseases.

The article also claims that Indian farmers need to buy seeds repeatedly. The fact is that not just biotech cotton, but all hybrid seeds lose their benefits if replanted, creating reduced and erratic yields. New seeds help farmers sustain high yields year on year.

In the case of biotech cotton in India, it is the farmers who adopted the technology wholeheartedly because they saw a solution in it to some of their biggest on-field pest challenges. The choice made by the Indian farmer to plant hybrid cotton seeds on over 90% of cotton acreage, and see increased cotton production is testament to the value created by better seeds, technologies and farming practices when compared with the alternative of low tech seed and insecticide sprays.

Bt cotton was released in varieties by some public institutions but it did not get much traction. There is always a debate about the use of hybrids versus varieties in any crop. The writer appears to be giving too much power to the seed industry in terms of influencing the farmer to prefer hybrids over varieties. This has not happened in the case of rice, mustard, many oilseeds, and pulses in which the farmers grow varietal crops in 90-100% of the area. The lesson is that the farmer adopts technologies which are beneficial to him and does not go by the recommendations of the industry or any other persons.

Seeds with biotechnologies have helped conserve biodiversity: with higher production from the same area, the expansion of agricultural land into forest areas has been slowed.

A one-sided depiction not only harms agriculture and the industry but also spreads misconceptions about biotechnology.

Ram Kaundinya is Director General, Federation of Seed Industry of India (FSII), New Delhi

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

View original post here:
A case of wholehearted biotechnology adoption - The Hindu

House bill seeks to eliminate regulations that hamper commercial release of biotech products – Manila Bulletin

Published January 22, 2020, 8:24 AM

By Charissa Luci-Atienza

The House Committee on Science and Technology has approved a bill seeking to eliminate the regulatory complications hampering the commercial release of biotechnology products.

Bohol Rep. Erico Aristotle Aumentado (FACEBOOK / FILE PHOTO / MANILA BULLETIN)

The House panel, chaired by Bohol Rep. Erico Aristotle Aumentado, passed House Bill No. 3372, the proposed Modern Biotechnology Act, principally authored by AAMBIS-OWA Party-list Rep. Sharon Garin.

We already approved the bill with minor amendments. It aims to promote safe and responsible use of biotechnology, he told the Manila Bulletin in a text message.

The bill was passed on Tuesday or more than a month after the Department of Agriculture-Bureau of Plant Industry (DA-BPI) affirmed the safety of GR2E Golden Rice for direct use as food and feed, or for processing (FFP). A bio-safety permit was issued to the Philippine Rice Research Institute (PhilRice) and International Rice Research Institute (IRRI) for GR2E Golden Rice.

Aumentado said the bill will be referred to the House Committee on Appropriations, chaired by Davao City Rep. Isidro Ungab and House Committee on Ways and Means, chaired by Albay Rep. Joey Salceda for their scrutiny.

Then, after the two panels pass the bill, we will have our committee report and the bill will be reported out to the plenary for its approval, he said.

Garin, main proponent of bio-fortification since the 17th Congress, earlier called on the House leadership to pass her bill.

We are trying to dispel the notion that commercially-produced bio-fortified goods are potentially dangerous, she said.

It is time that safe and responsible use of biotechnology be included in the Philippine toolkit to meet national development goals, she added.

Garin noted the National Economic and Development Authority (NEDA) recognizes agricultural biotechnology as a priority sector and has a direct impact on AmBisyon Natin 2040.

Biotechnology will increase yields and better products, leading to more income for farmers, she said.

Citing 2015 statistics, Garin said the average poverty incidence in the Philippines is about 21.6 percent and is highest among farmers at 34.4 percent.

She sought the passage of House Bill No. 3372, the proposed Modern Biotechnology Act, that calls for the creation of the Biotechnology Authority of the Philippines (BioAP) to promote safe and responsible use of biotechnology in the country.

In her bills explanatory note, Garin said HB 3372 seeks to expedite the regulatory decision-making process in biotechnology to help ensure the health and well-being of Filipinos, promote competitiveness, help reduce hunger and poverty, and help mitigate the effects of climate change.

She sought the revision of the current regulatory regime to enable the Philippines to benefit from products of modern biotechnology without delay, believing that that it is still based on outdated knowledge and assumptions.

Right now, it takes 65 months or more to complete all requirements for the commercial release of modern biotechnology products. The cumbersome regulations can no longer be justified for they effectively discriminate against local public biotech research institutions which have limited resources to comply with the existing regulations, Garin, chairman of the House Committee on Economic Affairs, said.

Aside from increasing yields and better products that would lead to more income for countrys farmers, Garin said biotechnology will provide climate and weather resistant crops that will mitigate the effects of natural disasters.

Since the 1980s, modern biotechnology has developed many useful products. These include insulin and corn that are resistant to borers and to a specific herbicide. These GMO corn plants have helped keep livestock and poultry affordable, and improved the profitability of 406,000 small resource poor Filipino farmers, Garin said.

HB 3372 tasks the BioAP to provide leadership in biotechnology industry development and rationalize the regulation of modern biotechnology. The proposed Biotechnology Authority shall also provide sustained funding for modern technology programs in agriculture, agroforestry, food processing, health, and manufacturing high value products for local and international markets.

The BioAP, under the bill, shall be attached to function as an agency of the DOST.

The bill calls for the abolition of the National Committee on Biosafety of the Philippines (NCBP) and other modern biotech regulatory bodies, but their functions shall be absorbed by the BioAP.

Sitting as members of the BioAP are the DOST Secretary or a designated Undersecretary, four members to be recommended by the National Academy of Science and Technology of the Philippines (NASTPhil), and two members to be recommended by the Philippine Chamber of Commerce and Industry (PCCI).

The BioAP shall have a Secretariat headed by an Executive Director to be appointed by the President of the Philippines upon the recommendation of the DOST Secretary.

Garin said under her bill, the BioAP shall ensure that the government formulates and strictly implements science-based bio-safety guidelines and regulations.

HB 3372 provides that the following acts shall be prohibited and penalized: unauthorized destruction of biotech crops, whether the crops are used for experimental objectives or for production; sale or distribution of fake genetically modified organism (GMO) seeds; and any other acts that are inimical to the safe and responsible use of modern biotechnology and are violative of the regulations set by the BioAP.

The bill provides that if violation is committed by an individual, he or she shall be penalized with two years of imprisonment and/or fine amounting to P500,000.

If the violator is an institution or organization, a P10-million fine and/or suspension of privilege to operate within the Philippines shall be imposed.

Garins bill also provides that any donation, contribution, bequest, subsidy, or financial aid to the BioAP or any Department, state university and college (SUC), or research center in support of modern biotechnology shall constitute allowable deductions from taxable income of the donor, and shall be exempt from donors tax.

An initial funding of P500 million shall be allotted for the operations of the BioAP and the needed appropriations for the full implementation of the proposed Act shall be included in the annual General Appropriations Act, the measure provides.

Within six months following the effectivity of the proposed Act, the DOST Secretary and the BioAP Executive Director shall activate the BioAP and it is expected that within three months, the BioAP members will promulgate the implementing rules and regulations of the proposed Act.

View original post here:
House bill seeks to eliminate regulations that hamper commercial release of biotech products - Manila Bulletin

Biotechnology and food security – The News International

Biotechnology and food security

Pakistan was one of the earliest countries to show interest in biotechnology, starting with the nomination to host an international biotechnology research center back in 1981. Despite all the early promise, the country has not fully benefitted from this innovation. The country has a long-standing policy to adopt biotechnology, reflected in the establishment and funding of numerous research institutes and academic programmes across the country since 1994. However, the government and its relevant ministries must provide an enabling environment to introduce innovative technologies in accordance with international standards.

In view of the above, there is a strong need for adopting biotechnology to grow enough food for a growing population while using fewer resources. Also there is a need for government ministries and departments to create policies and reforms backed by science rather than disinformation and anti-science propaganda. The country should also establish a legal and regulatory environment that is conducive to investment and transfer of technology. Also, the country must take advantage of the latest technologies, in particular biotechnology, for the advancement of agriculture.

Khan Faraz

Peshawar

Visit link:
Biotechnology and food security - The News International

Global Biotechnology Market : Analysis And Forecast 2019 2026 – Fusion Science Academy

Global Biotechnology Marketis expected to grow at a CAGR of 14% to reach US$ 1,254.1 million in 2024.

The growth is coupled with rising demand of modern and innovative technologies such as DNA sequencing, recombinant technology, fermentation, tissue engineering. Further, rising demand for food to meet the need of ever increasing population and scarce availability of non-renewable natural resources also expected to drive the biotechnology market. Application of Genetic engineering and Genetic Modification (GM) processes to agricultural food products also expected to drive the business growth. Furthermore, decreasing prices of DNA sequencing technologies will encourage R&D activities to better understand genetic variations and develop therapeutic solutions.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/10844

Moreover, development of novel techniques and their implementation by the organisation by collaborating with the other participants will drive the Global Biotechnology Market. Further, increasing demand for therapeutic and diagnostic solutions on principles of red biotechnology, DNA sequencing, and recombinant technology is expected to drive the Global Biotechnology Market through 2024. Increasing prevalence of diseases such as hepatitis B, cancer, and other orphan disorders is also expected to fuel demand in the forecast period.

In 2017, North America dominated the overall market. The market growth is driven by the increasing R&D investments relating to new drug discovery and development. U.S. held highest market in North America due to increasing level of per capita spending on healthcare than other countries and has a high growth rate amongst other countries. According to the estimates published by OECD Health Statistics in 2014, it has been estimated that in 2012, U.S. spent nearly 16.9% of its GDP towards healthcare expenditure, which is the highest. The fact supports the estimated share of Global Biotechnology Market.

Asia Pacific is expected to have higher growth rate in the forecast period owing to the presence of patient awareness, rapidly improving healthcare infrastructure, and rising healthcare expenditure levels in the emerging markets. Global Biotechnology Market include the developing economies of China and India.

In 2017, nanobiotechnology held the highest market share. The Global Biotechnology Market growth is driven by fermentation and cell-based assay segments owing to rising R&D initiatives by various biotechnological and pharmaceutical companies.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/10844

Global Biotechnology Market

Market Segmentation By Technologyo DNA Sequencingo Nanobiotechnologyo Tissue engineering and Regenerationo Fermentationo Cell Based Assayo PCR Technologyo Chromatography Marketo Others

By Applicationso Healtho Food & Agricultureo Natural Resources & Environmento Industrial Processingo Bioinformaticso Others

The above data will be provided for following regions/countries from 2013-2024 (USD Million)

North Americao U.S.o Canada

Europeo Germanyo UKo Franceo Spaino Italy

Asia Pacifico Chinao Indiao Japano Australia

Latin Americao Argentinao Brazilo Mexico

Middle East and Africao South Africao Saudi Arabia

MAJOR TOC OF THE REPORT

Chapter One: Biotechnology Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Biotechnology Market Competition, by Players

Chapter Four: Global Biotechnology Market Size by Regions

Chapter Five: North America Biotechnology Revenue by Countries

Chapter Six: Europe Biotechnology Revenue by Countries

Chapter Seven: Asia-Pacific Biotechnology Revenue by Countries

Chapter Eight: South America Biotechnology Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Biotechnology by Countries

Chapter Ten: Global Biotechnology Market Segment by Type

Chapter Eleven: Global Biotechnology Market Segment by Application

Chapter Twelve: Global Biotechnology Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Biotechnology Market Report at:https://www.maximizemarketresearch.com/market-report/global-biotechnology-market/10844/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

See the rest here:
Global Biotechnology Market : Analysis And Forecast 2019 2026 - Fusion Science Academy